Heidelberg Pharma AG · ISIN: DE000A11QVV0 · EQS - Company News

Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024

PRESS RELEASE Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024 Ladenburg, Germany, 6 November 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting, taking place from 7-10 December 2024 in San D...

XETR:HPHA Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Heidelberg Pharma AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (10)
Short Selling (DE) (0)
Short Selling (UK) (0)
06 November 2024 10:02AM
Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024 Ladenburg, Germany, 6 November 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based AD...
Heidelberg Pharma AG
About the publication
24 October 2024 11:03AM
Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024 Ladenburg, Germany, 24 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), announces it will present its ADC candidates and ADC technology platforms at leading scien...
Heidelberg Pharma AG
About the publication
10 October 2024 07:06AM
Interim Management Statement on the First Nine Months of 2024
DE000A11QVV0
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024 HDP-101 clinical trial in Europe and US continues with adjusted protocol and dose optimization on track; sixth patient cohort dosed at 90 µg/kg and patients are still on treatment Sale of a portion of future royalties for TLX250-CDx to HealthCare Royalty New cli...
Heidelberg Pharma AG
About the publication
01 October 2024 05:29PM
New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient Data from the study with the lead ADC candidate, HDP-101, show elimination of tumor cells in one patient Clinical data from IMS will be presented in R&D webinar on 15 October at 17:00 CEST / 1...
Heidelberg Pharma AG
About the publication
01 October 2024 03:27PM
Heidelberg Pharma AG Announces Updated Guidance
DE000A11QVV0
Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma AG Announces Updated Guidance Ladenburg, Germany, 1 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it has adjusted it...
Heidelberg Pharma AG
About the publication
23 September 2024 01:05PM
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024 Ladenburg, Germany, 23 September 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from...
Heidelberg Pharma AG
About the publication
23 September 2024 01:05PM
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024 Ladenburg, Germany, 23 September 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from...
Heidelberg Pharma AG
About the publication
11 July 2024 07:05AM
Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business First preliminary efficacy data from the clinical trial with HDP-101 in multiple myeloma published Presentation of preclinical and clinical data of the proprietary ADC technology platforms at the AACR Meeting 2024 HDP-101 granted Orphan Drug Designation ...
Heidelberg Pharma AG
About the publication
21 June 2024 11:16AM
Heidelberg Pharma reports on the results of the Annual General Meeting 2024
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma reports on the results of the Annual General Meeting 2024 Ladenburg, Germany, 21 June 2024 – Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a large majority (between 98,35% and 99,99%) at yesterday's ordinary virtual Annu...
Heidelberg Pharma AG
About the publication
18 June 2024 01:47PM
Heidelberg Pharma AG announces updated guidance
DE000A11QVV0
Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma AG Announces Updated Guidance Ladenburg, Germany, 18 June 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it has adjusted its ...
Heidelberg Pharma AG
About the publication
23 May 2024 09:12AM
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024 Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating...
Heidelberg Pharma AG
About the publication
23 May 2024 09:12AM
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024 Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating...
Heidelberg Pharma AG
About the publication
25 April 2024 07:21AM
Interim Management Statement on the First Three Months of 2024
DE000A11QVV0
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024 First efficacy data from the clinical trial with HDP-101 in multiple myeloma Professor Andreas Pahl becomes Chief Executive Officer Successful financing activities Sale of a portion of future royalties for Zircaix™ to HealthCare Royalty finances further develo...
Heidelberg Pharma AG
About the publication
05 April 2024 09:30AM
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma to host R&D Webinar following novel data presented at AACR Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST...
Heidelberg Pharma AG
About the publication
05 April 2024 09:30AM
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma to host R&D Webinar following novel data presented at AACR Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST...
Heidelberg Pharma AG
About the publication
27 March 2024 09:01AM
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 Ladenburg, Germany, 27 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has g...
Heidelberg Pharma AG
About the publication
25 March 2024 07:10AM
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma announces financial figures and reports on successful business performance in 2023 First efficacy data from the clinical trial with HDP-101 in multiple myeloma Expansion of the ADC technology platform to include further payloads New Management Board team Successful financing activities; sales revenue and other i...
Heidelberg Pharma AG
About the publication
19 March 2024 09:47AM
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty Ladenburg, Germany, 19 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today ann...
Heidelberg Pharma AG
About the publication
18 March 2024 07:25AM
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study Data from HDP-101 dose escalation shows first objective responses and partial remissions in Cohort 5 Amended protocol includes expanded Cohort 6 with dose optimization, including three parallel arms a...
Heidelberg Pharma AG
About the publication
06 March 2024 07:46AM
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024 Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs) will be presenting first efficacy data on its P...
Heidelberg Pharma AG
About the publication
04 March 2024 11:19AM
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranche...
Heidelberg Pharma AG
About the publication
04 March 2024 11:02AM
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
DE000A11QVV0
Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) H...
Heidelberg Pharma AG
About the publication
29 November 2023 12:05PM
Heidelberg Pharma Announces Changes to the Executive Management Board
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Announces Changes to the Executive Management Board CEO Dr. Jan Schmidt-Brand to retire His successor will be Prof. Dr. Andreas Pahl, Chief Scientific Officer Ladenburg, Germany, 29 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that Dr. Jan Schmidt-Brand, Chief Executive Officer (CEO) of Heidelb...
Heidelberg Pharma AG
About the publication
29 November 2023 11:56AM
Heidelberg Pharma Announces Changes to the Executive Management Board
DE000A11QVV0
Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Announces Changes to the Executive Management Board Ladenburg, Germany, 29 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that Dr. Jan Schmidt-Brand, Chief Executive Officer (CEO) of Heidelberg Pharma AG and Ma...
Heidelberg Pharma AG
About the publication
15 November 2023 09:24AM
Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO). Site-specific AT...
Heidelberg Pharma AG
About the publication
02 November 2023 04:34PM
Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023 Ladenburg, Germany, 2 November 2023 – Heidelberg Pharma AG (FSE: HPHA) will present new findings of its clinical Phase I/IIa study with the proprietary ADC candidate HDP-101 at the 65th Annual Meeting of the American Society o...
Heidelberg Pharma AG
About the publication
12 October 2023 07:09AM
Interim Management Statement on the First Nine Months of 2023
DE000A11QVV0
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023 HDP-101 clinical trial in Europe and US continues with adjusted protocol and larger number of study sites in Europe; fifth patient cohort initiated at 100 µg/kg dosing Patient from third cohort continues to be dosed and shows stable disease Divestment of minorit...
Heidelberg Pharma AG
About the publication
19 September 2023 07:11AM
Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101 First four patient cohorts and dose levels have been completed and proved to be safe and well tolerated Enrollment for fifth cohort with a dose of 100 µg/kg has already started Patient from third cohort continues to be dosed and shows no pr...
Heidelberg Pharma AG
About the publication
08 August 2023 07:46AM
Heidelberg Pharma’s Partner Takeda Reached Development Milestone
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma’s Partner Takeda Reached Development Milestone Ladenburg, Germany, 8 August 2023 – Heidelberg Pharma AG (FSE: HPHA) announced today that its partner Takeda reached a development milestone for starting a GLP (Good Laboratory Practice) toxicology study for an Antibody Targeted Amanitin Conjugate. Upon achievement of ...
Heidelberg Pharma AG
About the publication
13 July 2023 07:04AM
Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business Clinical trial with HDP-101 continues with adjusted protocol and larger number of study sites in Europe Patient from 3rd cohort continues to be dosed and shows stable disease Partnership with Magenta terminated due to clinical events and strategy change ...
Heidelberg Pharma AG
About the publication
13 July 2023 07:04AM
Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business Clinical trial with HDP-101 continues with adjusted protocol and larger number of study sites in Europe Patient from 3rd cohort continues to be dosed and shows stable disease Partnership with Magenta terminated due to clinical events and strategy change ...
Heidelberg Pharma AG
About the publication
29 June 2023 09:45AM
Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics
DE000A11QVV0
Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics US pharma company Eli Lilly and Company acquires all shares of ADC developer Emergence Therapeutics Heidelberg Pharma is one of the founding investors and will receive about...
Heidelberg Pharma AG
About the publication
29 June 2023 09:45AM
Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics
DE000A11QVV0
Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics US pharma company Eli Lilly and Company acquires all shares of ADC developer Emergence Therapeutics Heidelberg Pharma is one of the founding investors and will receive about...
Heidelberg Pharma AG
About the publication
25 May 2023 03:17PM
Heidelberg Pharma reports on the results of the Annual General Meeting 2023
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma reports on the results of the Annual General Meeting 2023 Ladenburg, Germany, 25 May 2023 - Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a large majority (between 96,30 % and 99,99 %) at today's ordinary virtual Annual...
Heidelberg Pharma AG
About the publication
25 May 2023 03:17PM
Heidelberg Pharma reports on the results of the Annual General Meeting 2023
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma reports on the results of the Annual General Meeting 2023 Ladenburg, Germany, 25 May 2023 - Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a large majority (between 96,30 % and 99,99 %) at today's ordinary virtual Annual...
Heidelberg Pharma AG
About the publication
05 May 2023 12:25PM
Heidelberg Pharma appoints Chief Financial Officer
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma appoints Chief Financial Officer Ladenburg, Germany, 5 May 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that Walter Miller has been appointed Chief Financial Officer effective 1st May 2023. Dr. Jan Schmidt-Brand, who has served in a dual role since 2014, will remain Spokesman of the Management Board/CEO ...
Heidelberg Pharma AG
About the publication
05 May 2023 12:25PM
Heidelberg Pharma appoints Chief Financial Officer
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma appoints Chief Financial Officer Ladenburg, Germany, 5 May 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that Walter Miller has been appointed Chief Financial Officer effective 1st May 2023. Dr. Jan Schmidt-Brand, who has served in a dual role since 2014, will remain Spokesman of the Management Board/CEO ...
Heidelberg Pharma AG
About the publication
13 April 2023 07:10AM
Interim Management Statement on the First Three Months of 2023
DE000A11QVV0
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023 Initial findings of HDP-101 presented at ASH Annual Meeting Signing of a partnership with Binghamton University Termination agreement signed with Magenta Financials in line with planning Ladenburg, Germany, 4 April 2023 - Heidelberg Pharma AG (FSE: HPHA) today...
Heidelberg Pharma AG
About the publication
13 April 2023 07:10AM
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
DE000A11QVV0
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023 Initial findings of HDP-101 presented at ASH Annual Meeting Signing of a partnership with Binghamton University Termination agreement signed with Magenta Financials in line with planning Ladenburg, Germany, 4 April 2023 - Heidelberg Pharma AG (FSE: HPHA) today...
Heidelberg Pharma AG
About the publication
04 April 2023 10:12AM
Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023 Ladenburg, Germany, 4th April 2023 – Heidelberg Pharma AG (FSE: HPHA) will present data from preclinical studies at this year's American Association for Cancer Research (AACR) annual meeting that provide positive...
Heidelberg Pharma AG
About the publication
04 April 2023 10:12AM
Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023 Ladenburg, Germany, 4th April 2023 – Heidelberg Pharma AG (FSE: HPHA) will present data from preclinical studies at this year's American Association for Cancer Research (AACR) annual meeting that provide positive...
Heidelberg Pharma AG
About the publication
24 March 2023 07:11AM
Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business Start of clinical trial and first safety data with HDP-101 in multiple myeloma Conclusion and implementation of a strategic partnership with Huadong Medicine Successful financing activities Financials in line with adjusted guidance ...
Heidelberg Pharma AG
About the publication
24 March 2023 07:11AM
Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business Start of clinical trial and first safety data with HDP-101 in multiple myeloma Conclusion and implementation of a strategic partnership with Huadong Medicine Successful financing activities Financials in line with adjusted guidance ...
Heidelberg Pharma AG
About the publication
16 December 2022 09:55AM
Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform Ladenburg, Germany, 16 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that it has entered into a research and exclusive option agreement with Binghamton University, State University of...
Heidelberg Pharma AG
About the publication
16 December 2022 09:55AM
Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform Ladenburg, Germany, 16 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that it has entered into a research and exclusive option agreement with Binghamton University, State University of...
Heidelberg Pharma AG
About the publication
14 December 2022 03:43PM
Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022
DE000A11QVV0
PRESS RELEASE Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022 Ladenburg, Germany, 14 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that initial clinical data from two Antibody Drug Conjugates (ADCs) based on the Company’s proprieta...
Heidelberg Pharma AG
About the publication
14 December 2022 03:43PM
Heidelberg Pharma AG: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022
DE000A11QVV0
PRESS RELEASE Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022 Ladenburg, Germany, 14 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that initial clinical data from two Antibody Drug Conjugates (ADCs) based on the Company’s proprieta...
Heidelberg Pharma AG
About the publication
10 November 2022 03:24PM
Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022
DE000A11QVV0
PRESS RELEASE Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022 Heidelberg Pharma presents initial findings of the first in human study with ATAC® candidate HDP-101 Licensing partner Magenta presents initial data from Phase I/II study with ATAC® candidate MGTA-...
Heidelberg Pharma AG
About the publication
More Heidelberg Pharma AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 10 29th August 2024 Miller, Walter DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN